AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00808665
Drug: 0.9% Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the placebo arm will receive an equal per-kg IV volume of 0.9% Sodium Chloride over the same periods. Drug administration will be controlled for both arms of the study using a continuous infusion pump.
Trial: NCT01363232
Drug: BKM120 + MEK162
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02967393
Drug: ccIIV4
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00800085
Drug: glucose 20%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: maintain glycemia at 180 mg/dL till 150 min. after start glucose infusion: with a maintenance dose computed at 5- to 10-minute intervals
Trial: NCT01438281
Drug: SYL1001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYL1001 eye drops. topical administration
Trial: NCT04033926
Drug: KZR-616
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous 30 mg weekly for 2 weeks, then 45 mg weekly for 14 weeks
Trial: NCT04033926
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection for 16 weeks
Trial: NCT00746681
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, Oral, twice daily for 4 weeks
Trial: NCT01578447
Drug: DepoSubQ Provera 104 in Uniject
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DepoSubQ Provera 104 in Uniject
Trial: NCT03910634
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1.33g/body surface QW1, continuous intravenous infusion for 72 hours, repeated for 4 weeks
Trial: NCT04098003
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: rosuvastatin 20 mg daily or placebo for eight weeks
Trial: NCT04098003
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo control
Trial: NCT03448406
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablet
Trial: NCT01473108
Drug: Eplerenone (Inspra®)
RxNorm normalized name: eplerenone Oral Tablet [Inspra]
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single oral dose of 50 mg eplerenone
Trial: NCT01473108
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo (solution/tablet) corresponding to BAY 94-8862 dose in respective dose step
Trial: NCT04197245
Drug: saline injection therapy in post-acne atrophic scars
RxNorm normalized name: Scar Zone A Acne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline injection contains 0.9% isotonic sodium chloride solution
Trial: NCT01670084
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01670084
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01670084
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV or IT
Trial: NCT01670084
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01424384
Drug: GSK424887
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurophysiological testing
Trial: NCT01424384
Drug: Plactebo To Match
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurophysiological testing
Trial: NCT02101866
Drug: Vapendavir 300 mg tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet - single dose
Trial: NCT02101866
Drug: Vapendavir 132 mg capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 capsules - single dose
Trial: NCT05104138
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients underwent eplerenone treatment for 6 months
Trial: NCT01713920
Drug: SEVIKAR
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01081002
Drug: Diluted gentian root solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As a basis, an infusion of water (45%), ethanol (35%) and gentian root cut will be used. The gentian root infusion is approved as a natural flavor in the food industry.3 min before the endoscopy under propofol sedation 4 puffs of this gentian root infusion will be sprayed on the pharynx as a pharyngeal anesthesia
Trial: NCT00287261
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 4 mg IV every 3 weeks for 36 weeks
Trial: NCT04606225
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of placebo (oral)
Trial: NCT00658918
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00212108
Drug: celecoxib, gefitinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose of ZD1839 to be administered is 250mg. ZD1839 will be taken once daily in the morning at approximately the same time each day. If the patient inadvertently did not take the dose in the morning, the patient may take that dose anytime up to 10pm that same day. The daily treatment will be resumed the next day at the scheduled morning dose. Celecoxib will be administered at 400 mg bd.
Trial: NCT02866786
Drug: ethinyl estradiol and cyproterone acetate
RxNorm normalized name: cyproterone / ethinyl estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Contraceptive Pill
Trial: NCT02307825
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The drug will be taken three times a week for four months.
Trial: NCT02307825
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo will be taken three times a week for four months.
Trial: NCT02592980
Drug: Traditional anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The physician will adjust the dose according to current INR value based on guidelines.
Trial: NCT01377194
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to be given orally, in capsule form, once daily, for 8 weeks.
Trial: NCT03204331
Drug: Estradiol/norethindrone acetate
RxNorm normalized name: Estradiol/Norethindrone Acetate 1 MG-0.5 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule containing co-formulated tablet of E2 (1.0 mg)/NETA (0.5 mg) administered orally once daily.
Trial: NCT03204331
Drug: Estradiol/norethindrone acetate placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the E2/NETA capsule in size, shape, color, and odor.
Trial: NCT00529594
Drug: placebo (Control Group)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both medication have been given to the patients in both groups 1 hour prior the laser photocoagulation
Trial: NCT00529594
Drug: Etoricoxib (Treatment Group)
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both medication have been given to the patients in both groups 1 hour prior the laser photocoagulation
Trial: NCT03772249
Drug: Placebo for DCR-HBVS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile 9% saline for injection.
Trial: NCT03234595
Drug: Cerebraca wafer
RxNorm normalized name: Sus scrofa cerebral cortex preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible patients will receive Cerebraca wafer implantation with adjuvant temozolomide (TMZ) for the safety and efficacy in this study. At Phase I, the MTD will be determined by DLT. At Phase IIa, up to 12 evaluable patients will be enrolled for the efficacy and safety of Cerebraca wafer implantation. At Phase IIa, the cavity surface after tumor removal will be maximally covered by Cerebraca wafer without exceeding the MTD defined at Phase I. Patients in Phase I receive treatment as designed for Phase IIa, the data will be incorporated into Phase IIa to reduce the patient number. The overall patient number in this study is therefore between 2 to 36 evaluable patients.
Trial: NCT02623972
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: administered IV with adriamycin for 4 cycles
Trial: NCT01108588
Drug: Placebo (to match Aspirin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo grossly matched Aspirin 300 mg daily
Trial: NCT01108588
Drug: Comparator: Placebo (to match Clopidogrel)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (grossly matched Clopidogrel 75 mg) daily
Trial: NCT00422227
Drug: Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Methotrexate: at least 7.5 mg/wk and not more than 25 mg/wk.;PO~* Sulfasalazine: Start treatment w/500 mg daily for 1 wk, thereafter increase dose by 1 tab each wk to a max of 3 g/day;PO~* Hydroxychloroquine:400 mg daily in divided dose, may be reduced to 200 mg. Max: 6.5 mg/kg/day~* Leflunomide: Initially, loading dose 100 mg daily for 3 days. Maintenance: 20 mg daily
Trial: NCT03418727
Drug: Corticosteroid Eye Drop
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eye drop to be administered after Brimonidine in treatment arm 1
Trial: NCT01207427
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01207427
Drug: ADL5945 0.1 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01207427
Drug: ADL5945 0.25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02380573
Drug: FD&C Blue # 2
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01375491
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: generic doxycycline 100mg twice daily
Trial: NCT03755713
Drug: ASP0892
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal
Trial: NCT03755713
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal; normal saline solution
Trial: NCT00020488
Drug: FOLFIRI regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00020488
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00020488
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02056808
Drug: SMT C1100
RxNorm normalized name: ZINC OXIDE 2.94 g in 100 g / TITANIUM DIOXIDE 2.4 g in 100 g / OCTINOXATE 7 g in 100 g TOPICAL CREAM [sMTS Dual HA SUN BLOCK]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of safety and pharmacokinetic of different dosages of drug
Trial: NCT00240331
Drug: 10mg Rosuvastatin
RxNorm normalized name: rosuvastatin 10 MG
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00240331
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02010099
Drug: PP110 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02127866
Drug: CHF 5259 plus Foster 100/6 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of different doses of CHF 5259 (on top of Foster 100 /6 µg) versus Foster 100/6 µg over a treatment period of 6 weeks. Each subject will be allocated to 3 ouf of the 4 possible treatments performed in sequence during a cross over design (incomplete block)
Trial: NCT02127866
Drug: Foster 100/6 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active comparator~Comparison of different doses of CHF 5259 (on top of Foster 100 /6 µg) versus Foster 100/6 µg over a treatment period of 6 weeks. Each subject will be allocated to 3 ouf of the 4 possible treatments performed in sequence during a cross over design (incomplete block)
Trial: NCT06597084
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets for oral administration, matching the test product. In case a patient is unable to swallow the whole tablet, the tablet can be crushed or divided into equal doses at the score line.
Trial: NCT00755976
Drug: sulindac
RxNorm normalized name: Sulindac
DrugBank: Sulindac (DB00605)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04583410
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLACEBO OF NICOPATCHLIB, 7mg/24h Day 1 to day 3 : 3,5 mg/day Day 4 to day 9 : 7 mg/day Day 10 to Day 15 : 10,5 mg/day Day 16 to day 98 : 14 mg/day~Decrease treatment Day 99 to day 105 : 10,5 mg/day Day 106 to day 112 : 7 mg/day Day 113 to Day 119 : 3,5 mg/day
Trial: NCT05896605
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Before medication, TPMT activity was normal, and AZA was started at small doses and added every two weeks after no AEs, namely 50 mg qd for two weeks, 50mg bid for two weeks, and maintained at 50mg tid.
Trial: NCT04214145
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous infusion of Norepienphrine 20 μg/mL (=NE 4mg \* 1@ + D5W 200 mL) if mean BP \< 60mmHg.~1. Initial rate: 0.03 μg/kg/min (=0.1 mL/kg/hr)~2. Increment by 0.015 μg/kg/min (=0.05 mL/kg/hr) if mean BP \< 60mmHg after 5 minutes~3. Maximum rate: 0.24 μg/kg/min (=0.8 mL/kg/hr)
Trial: NCT00218439
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02477215
Drug: MLN9708
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of MLN9708 delivered on days 1, 8 and 15 of a 28 day cycle.
Trial: NCT00285857
Drug: Lovastatin
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lovastatin 80 mg/day as 40 mg orally twice daily.~Lovastatin is approved by FDA as a cholesterol-lowering agent.
Trial: NCT04052425
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream is a topical formulation applied as a thin film to affected areas.
Trial: NCT03793517
Drug: mBU/CY and ATG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ara-C 4 g·m-2·d-1 intravenously on days -10 to -9 Busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, Cyclophosphamide (CY 1.8 g·m-2·d-1) intravenously on days -5 to -4 Simustine (Me-CCNU, 250 mg·m-2) orally once on day -3 ATG (2.5 mg·kg-1·d-1) intravenously on days -5 to -2
Trial: NCT03793517
Drug: mBU/CY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hydroxycarbamide (80 mg·kg-1) orally on day -10 Ara-C (2 g·m-2·d-1) on day -9 Busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, Cyclophosphamide (CY 1.8 g·m-2·d-1) intravenously on days -5 to -4 Simustine (Me-CCNU, 250 mg·m-2) orally once on day -3
Trial: NCT03182673
Drug: SHR7390
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR7390 is provided as white, film-coated,immediate release tablets containing SHR7390 at dosage strengths of 0.125 mg,0.5 mg and 2mg. Multiple tablets of SHR7390 will be administered orally to achieve targeted doses of SHR7390: 0.125 mg-4 mg. Tablets will be administered once daily or for 21 days and discontinued for 7 days with 240 ml water after 2 hours of the meal.
Trial: NCT06597825
Drug: root canal irrigation solutions (NaOCl+EDTA, NaOCl+HEDP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After cavity preparation with sterile burs, rubber dam components were applied to the tooth. The root canal filling material was removed via retreatment files. After the working length was determined, in all the groups, the canals were filled with distilled water. S1were taken from the canal after retreatment. Irrigation protocols were applied for 4 groups. S2 were taken from the canal. Intracanal medicament was placed in the root canal, the cavity was securely sealed. After 14 days,the medicament was removed with 10 mL of 17% EDTA and subsequently irrigated with 5 ml of distilled water, S3 was taken by sterile paper points. The final irrigation was performed according to the group to which the tooth belonged, and S4 was collected as before. the root canals were dried with sterile paper points and filled gutta-percha master cones and sealer.
Trial: NCT00612963
Drug: Frio Oral Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription Mouth Rinse
Trial: NCT03978949
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two weeks prior to the start of radiation therapy, the placebo is administered three times daily until the end of radiation therapy.
Trial: NCT00505765
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo- 3 sprays in each nostril, twice per day
Trial: NCT00505765
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo- one spray in each nostril, once per day
Trial: NCT00683852
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: for patients randomly assigned to the placebo/placebo sequence, study medication will be placebo during both phases of the study (60 days)
Trial: NCT03884829
Drug: CYC140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYC140 single agent
Trial: NCT02427334
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: women will receive oral fluoxetine 20mg for 14 days starting from the 15th day of menstruation
Trial: NCT02427334
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: women will receive oral placebo for 14 days starting from the 15th day of menstruation
Trial: NCT03520998
Drug: GRF6019
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GRF6019 for IV infusion
Trial: NCT00416910
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00910650
Drug: non-myeloablative conditioning chemotherapy
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive non-myeloablative conditioning chemotherapy with Cyclophosphamide 60 mg/kg/day x 2 days and Fludarabine 25 mg/m2/day i.v. over 30 minutes for 4 days
Trial: NCT00423579
Drug: Ezetimibe/Simvastatin 10/20 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet containing 10 mg of ezetimibe and 20 mg of simvastatin per day for 6 weeks
Trial: NCT00423579
Drug: simvastatin 40 mg
RxNorm normalized name: simvastatin 40 MG
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet containing 40 mg of simvastatin per day for 6 weeks
Trial: NCT03530215
Drug: Antineoplastic and Immunomodulating Agents
RxNorm normalized name: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antineoplastic agents, endocrine therapy, immunostimulants and immunosuppressants drugs included in the ATC classification L
Trial: NCT03794310
Drug: NPF-08 （1-day treatment）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPF-08 will be administered on the day of colonoscopy.
Trial: NCT03794310
Drug: NPF-08 （2-day split dose）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPF-08 will be administered at 2 days divided into the day before and on the day of colonoscopy.
Trial: NCT03794310
Drug: Moviprep（1-day treatment）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moviprep will be administered on the day of colonoscopy.
Trial: NCT01582932
Drug: Calcipotriene 0.005% Foam
RxNorm normalized name: CALCIPOTRIENE 0.005% FOAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face).
Trial: NCT03857854
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo group
Trial: NCT01795677
Drug: Ruxolotinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolotinib doses calculated with platelets count and P450 cytochrome inhibitor HSCT for patients with donor
Trial: NCT03697252
Drug: Placebo Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Capsules
Trial: NCT03125395
Drug: LUM/IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received LUM/IVA every q12h.
Trial: NCT01099722
Drug: Flutiform
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhaler 2 puffs bd daily
Trial: NCT03159052
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily, 24 weeks
Trial: NCT01099722
Drug: Symbicort Turbohaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 puffs bd daily
Trial: NCT02788552
Drug: Thiamine Hydrochloride
RxNorm normalized name: Thiamine Hydrochloride
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered Intravenously in 100ml bag of normal saline (0.9%) infused over 30 mins.
Trial: NCT02369874
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care
Trial: NCT03472339
Drug: Diclofenac Sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Group A-Intramuscular diclofenac sodium+oral placebo Group B-Oral diclofenac sodium+ intramuscular placebo
Trial: NCT03184688
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided normal saline injection between proximal carpal tunnel and median nerve.
Trial: NCT02080715
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04109547
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets to be taken once-daily for 26 weeks
Trial: NCT04218240
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral Placebo